Efficacy of Adapted Physical Activity on a Walking Platform in Elderly Patients HOspitalized for Cancer Surgery

NCT06201884 | Recruiting Phase 2

• 1 other identifier: 2023-A01292-43
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

The aim of this study was to evaluate the efficacy of daily use of a walking platform to improve recovery of preoperative walking speed at hospital discharge following oncological surgery in patients aged 65 or older.

Conditions

Oncology; Elderly Patients; Surgery

Keywords

Adapted physical activity; walking platform

Outcome Measures

Primary Outcomes (1)

• To evaluate the efficacy of daily use of a walking platform to improve recovery of preoperative walking speed at hospital discharge following oncological surgery in patients aged 65 or older.

  Proportion of patients having recovered their preoperative walking speed at hospital discharge

  at hospital discharge (approximately 15 to 30 days after surgery)

Study Arms (1)

Adapted physical activity

EXPERIMENTAL

Adapted physical activity on a walking platform

Device: Early rehabilitation through Adapted Physical Activity

Interventions

Early rehabilitation through Adapted Physical Activity DEVICE

From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.

Adapted physical activity

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Men or women aged 65 or over
• Candidate for scheduled major oncological surgery and/or surgery with high morbidity
• Patient able to walk for 10 minutes on the walking platform at the time of the test
• Patient affiliated to a social security system
• Signature of informed consent prior to any specific study-related procedure

You may not qualify if:

• Patient with severe undernutrition (BMI\<18, and/or weight loss \>15% in 6 months or \>10% in 1 month)
• Emergency surgery
• Physical contraindications preventing use of the platform
• Simultaneous participation in another clinical study that could compromise the conduct of this study
• Patients deprived of their liberty, under guardianship or subject to a legal protection measure, or unable to express their consent.
• Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons.

Sponsors & Collaborators

• Centre Francois Baclesse: lead

Study Sites (2)

Centre Francois Baclesse

Caen, France

RECRUITING

CHU CAEN

Caen, France

RECRUITING

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Heidi LAVIEC, MD

CONTACT

0231455050; h.laviec@baclesse.unicancer.fr

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2024
• First Posted: January 11, 2024
• Study Start: March 15, 2024
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: January 12, 2026

Record last verified: 2026-01

Locations

FR (2)